دورية أكاديمية
Expression of CD44, PCNA and E-cadherin in pterygium tissues.
| العنوان: | Expression of CD44, PCNA and E-cadherin in pterygium tissues. |
|---|---|
| المؤلفون: | Yıldırım H; Department of Ophthalmology, Balıkesir University, Faculty of Medicine, Balıkesir, Türkiye., Turan G; Department of Pathology, Balıkesir University, Faculty of Medicine, Balıkesir, Türkiye., Turan M; Balikesir Ataturk Cıty Hospital, Ophthalmology, Balikesir, Türkiye. |
| المصدر: | Indian journal of ophthalmology [Indian J Ophthalmol] 2024 May 01; Vol. 72 (Suppl 3), pp. S501-S504. Date of Electronic Publication: 2024 Apr 20. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medknow Publications Country of Publication: India NLM ID: 0405376 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-3689 (Electronic) Linking ISSN: 03014738 NLM ISO Abbreviation: Indian J Ophthalmol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Mumbai : Medknow Publications Original Publication: Bombay : All-India Ophthalmological Society |
| مواضيع طبية MeSH: | Cadherins*/metabolism , Cadherins*/biosynthesis , Conjunctiva*/metabolism , Conjunctiva*/pathology , Hyaluronan Receptors*/metabolism , Hyaluronan Receptors*/genetics , Hyaluronan Receptors*/biosynthesis , Proliferating Cell Nuclear Antigen*/metabolism , Proliferating Cell Nuclear Antigen*/biosynthesis , Pterygium*/diagnosis , Pterygium*/metabolism , Pterygium*/pathology, Female ; Humans ; Male ; Biomarkers/metabolism |
| مستخلص: | Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. However, its pathogenesis remains unclear. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence. Methods: Sixty patients with pterygium participated in the study, and we collected conjunctival samples from 30 patients to form a control group. CD44, PCNA, and E-cadherin expressions in surgically excised pterygium were compared with tissue samples from the control group. Results: We observed that the percentages of CD44 and PCNA were statistically higher in the primary pterygium group and recurrent pterygium group than in the control group (P < 0.001 and P < 0.001, respectively). Conversely, E-cadherin values were statistically higher in the control group than in the primary and recurrent pterygium groups (P = 0.013 and P < 0.001, respectively). Conclusion: Cell proliferation and cell adhesion factors may play important roles in the pathogenesis of pterygium. (Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.) |
| References: | Lin A, Stern G. Correlation between pterygium size and induced corneal astigmatism. Cornea 1998;17:28–30. Liu T, Liu Y, Xie L, He X, Bai J. Progress in the pathogenesis of pterygium. Curr Eye Res 2013;38:1191–7. Palewski M, Budnik A, Konopińska J. Evaluating the efficacy and safety of different pterygium surgeries: A review of the literature. Int J Environ Res Public Health 2022;19:11357. Cárdenas-Cantú E, Zavala J, Valenzuela J, Valdez-García JE. Molecular basis of pterygium development. Semin Ophthalmol 2016;31:567–83. Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: Role of cytokines, growth factors, and matrix metalloproteinases. Progr Retin Eye Res 2004;23:195–228. Anguria P, Kitinya J, Ntuli S, Carmichael T. The role of heredity in pterygium development. Int J Ophthalmol 2014;7:563–73. Linaburg T, Choi D, Bunya VY, Massaro-Giordano M, Briceño CA. Systematic review: The effects of pterygium and pingueculum on the ocular surface and the efficacy of surgical excision. Cornea 2021;40:258–67. Nuzzi R, Tridico F. How to minimize pterygium recurrence rates: Clinical perspectives. Clin Ophthalmol 2018;12:2347–62. Al Fayez MF. Limbal-conjunctival vs conjunctival autograft transplant for recurrent pterygia: A prospective randomized controlled trial. JAMA Ophthalmol 2013;131:11–6. Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function and association with the malignant process. In: Vande Woude GF, Klein G, editors. Advances in Cancer Research. Vol. 71. San Diego: Academic Press; 1997. p. 241–319. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999;51:189–96. Kelman Z. PCNA: Structure, functions and interactions. Oncogene 1997;14:629–40. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008;17:323–34. Semb H, Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum Genet 1998;63:1588–93. Li Z, Yin S, Zhang L, Liu W, Chen B. Prognostic value of reduced E-cadherin expression in breast cancer: A meta-analysis. Oncotarget 2017;8:16445–55. Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F, Jurka P. Role of cadherins in cancer—A review. Int J Mol Sci 2020;21:7624. Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol 1997;115:1235–40. Loh C-Y, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells 2019;8:1118. Kato N, Shimmura S, Kawakita T, Miyashita H, Ogawa Y, Yoshida S, et al. β-Catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci 2007;48:1511–7. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019;20:69–84. Umbas R, Isaacs WB, Bringuier PP, Schaafsma E, Karthaus HFM, Gosse ON, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929–33. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789–96. He X, Chen Z, Jia M, Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: Evidence from meta-analysis. PLoS One 2013;8:e70858. Zheng Y, Shi Y, Yu S, Han Y, Kank K, Xu H, et al. GTSE1, CDC20, PCNA, and MCM6 synergistically affect regulations in cell cycle and indicate poor prognosis in liver cancer. Anal Cell Pathol (Amst) 2019;2019:1038069. Lu EMC, Ratnayake J, Rich AM. Assessment of proliferating cell nuclear antigen (PCNA) expression at the invading front of oral squamous cell carcinoma. BMC Oral Health 2019;19:233. Guzińska-Ustymowicz K, Pryczynicz A, Kemona A, Czyżewska J. Correlation between proliferation markers: PCNA, Ki-67, MCM–2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res 2009;29:3049–52. Liang K, Jiang Z, Ding B, Cheng P, Huang D, Tao L. Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva. Mol Vis 2011;17:1687–93. Kase S, Takahashi S, Sato I, Nakanishi K, Yoshida K, Ohno S. Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium. Br J Ophthalmol 2007;91:958–61. Turan M, Turan G. Bcl-2, p53, and Ki-67 expression in pterygium and normal conjunctiva and their relationship with pterygium recurrence. Eur J Ophthalmol 2020;30:1232–7. Bellizzi A, Sebastian S, Ceglia P, Centonze M, Divella R, Manzillo EF, et al. Co-expression of CD133+/CD44+in human colon cancer and liver metastasis. J Cell Physiol 2013;228:408–15. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+population in hepatocellular carcinoma. Int J Cancer 2010;126:2067–78. Chen Y, Fu Z, Xu S, Xu Y, Xu P. The prognostic value of CD44 expression in gastric cancer: A meta-analysis. Biomed Pharmacother 2014;68:693–7. Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z, et al. The prognostic and clinical value of CD44 in colorectal cancer: A meta-analysis. Front Oncol 2019;9:309. |
| المشرفين على المادة: | 0 (Biomarkers) 0 (Cadherins) 0 (CD44 protein, human) 0 (Hyaluronan Receptors) 0 (PCNA protein, human) 0 (Proliferating Cell Nuclear Antigen) 0 (CDH1 protein, human) |
| تواريخ الأحداث: | Date Created: 20240422 Date Completed: 20240429 Latest Revision: 20240509 |
| رمز التحديث: | 20240509 |
| DOI: | 10.4103/IJO.IJO_2579_23 |
| PMID: | 38648458 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1998-3689 |
|---|---|
| DOI: | 10.4103/IJO.IJO_2579_23 |